AbCellera Biologics Inc vs First Trust Cloud Computing ETF — how do they compare? AbCellera Biologics Inc trades at $9.98 (market cap $2.99B), while First Trust Cloud Computing ETF trades at $161.6. Which is the better fit depends on your goals.
| ABCL | SKYY | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | — |
52-Week High | $9.76 | $161.09 |
52-Week Low | $2.78 | $104.16 |
Enterprise Value | $2.58B | — |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
First Trust Cloud Computing ETF (SKYY) trades at $163.00, up 1.38% with bullish technical signals from moving averages and ADX indicators. The ETF provides diversified exposure to cloud infrastructure, software, and AI companies, benefiting from secular trends in cloud migration and AI adoption. Recent news highlights strong institutional interest in technology ETFs and SKYY's positioning in the expanding AI ecosystem beyond semiconductors.
SKYY offers exposure to cloud computing growth drivers with technical momentum supporting near-term upside. Key risks include technology sector volatility and competitive pressures from global cloud initiatives. The ETF's diversified approach mitigates concentration risk while capturing broader technology transformation trends.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →